Jennifer J. Schlezinger, PhD
Associate Professor
Boston University School of Public Health
Dept of Environmental Health

PhD, Massachusetts Institute of Technology
BS, Boston College



Dr. Schlezinger’s expertise is in the field of molecular toxicology and focused on how environmental toxicants usurp the function of ligand-activated transcription factors to disrupt physiological function. In the early part of her career, she focused on the aryl hydrocarbon receptor (AhR) and its activation by polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls. She collaborated with Dr. David Sherr, an immunologist, to determine how PAHs suppress B lymphocyte development and impair immune function. This led to her introduction to nuclear receptors, as she transitioned to investigate the effects of peroxisome proliferator activated receptor ? (PPAR?) ligands on B cell development. She found that PPAR? ligands were not only directly acting on the developing B cells, but also changing the microenvironment of the bone marrow, because PPAR? ligands skew multipotent cell differentiation from bone formation to adipose formation. For the past ten years, the overarching goal of her laboratory’s research is to determine how exposure to environmental toxicants impair bone, liver and adipose homeostasis, which lays the foundation for osteoporosis and metabolic disease. She has investigated nuclear receptor activation (e.g., PPAR?, RXRs, LXRs) in bone/adipocyte forming cells and the physiological impact of environmental chemical-driven changes in the activities of these receptors. She then expanded her focus to include examining the role of environmental toxicants in development of metabolic disease, showing that environmental PPAR? ligands contribute to the development of pathological adipose tissue and metabolic dyshomeostasis. Most recently, Dr. Schlezinger’s research has turned to investigating the effects of perfluoroalkyl substances (PFAS) on activation of diverse nuclear receptors (e.g., PPARa, CAR and PXR) and the consequences for metabolic and bone health. She also is currently investigating the interaction of SARS-CoV-2 infection with PFAS exposure with viral immunologist, Dr. Florian Douam (NEIDL). To conduct human relevant research on PFAS in animal models, she has developed novel animal models and experimental designs to maximize the applicability of the results to understanding adverse health effects in people.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease
03/02/2021 - 02/28/2023 (Multi-PI)
PI: Jennifer J. Schlezinger, PhD
NIH/National Institute of Environmental Health Sciences
5R21ES032882-02

Development of PPARy Ligand Exposure Biomarker
07/01/2016 - 06/30/2019 (Key Person / Mentor)
Environmental Protection Agency


Testing of Adipogenic ToxPi Compounds
07/20/2016 - 12/31/2017 (PI)
NIH/National Institute of Environmental Health Sciences


Receptor-based Developmental and Reproductive Toxicity of Superfund Chemicals
09/20/2012 - 03/31/2016 (Co-Investigator)
PI: David H. Sherr, PhD
NIH/National Institute of Environmental Health Sciences
5P42ES007381-19

Effects of High Fat Diet and Environmental Obesogen Co-Exposure on Osteoporosis
09/01/2012 - 08/31/2014 (PI)
NIH/National Institute of Environmental Health Sciences
5R21ES021136-02

Environmental PPAR Agonists Accelerate Aging of Bone and Impair Lymphopoiesis
09/01/2010 - 08/31/2014 (Key Person)
PI: Amelia Baker, MD, PhD
NIH/National Institute of Environmental Health Sciences
5F30ES019394-04

Testing of Adipogenic ToxPi Compunds
04/01/2012 - 12/31/2012 (Subcontract PI)
Professional & Scientific Associates NIH NIEHS


Molecular Mechanisms of Aryl Hydrocarbon Receptor - Mediated Breast Cancer
01/03/2000 - 12/31/2001 (PI)
Comm. of Mass./Department of Public Health

Aryl Hydrocarbon Receptor and NF-kappaB Interactions
08/24/2000 - 08/23/2001 (PI)
NIH/National Institute of Environmental Health Sciences
1 F32 ES05911 01



Title


Yr Title Project-Sub Proj Pubs
2023 Investigating the Perturbation of Bone Health by Per/Polyfluoroalkyl Substances 1R03ES034093-01A1
2022 Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease 5R21ES032882-02
2021 Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease 1R21ES032882-01
2019 Project 3: Environmental PPAR? Pathway Activators: Multifaceted Metabolic Disruptors Impacting Adipose and Bone Homeostatsis 5P42ES007381-23-8625 413
2018 Project 3: Environmental PPAR? Pathway Activators: Multifaceted Metabolic Disruptors Impacting Adipose and Bone Homeostatsis 5P42ES007381-22-8625 413
2017 Project 3: Environmental PPAR? Pathway Activators: Multifaceted Metabolic Disruptors Impacting Adipose and Bone Homeostatsis 2P42ES007381-21-8625 413
2013 Effects of High Fat Diet and Environmental Obesogen Co-Exposure on Osteoporosis 5R21ES021136-02 3
2012 Effects of High Fat Diet and Environmental Obesogen Co-Exposure on Osteoporosis 1R21ES021136-01 3
2010 Antagonism of the Ah Receptor in Controlling Breast Cancer Growth and Invasion 5R21CA134882-02 2
2009 Antagonism of the Ah Receptor in Controlling Breast Cancer Growth and Invasion 1R21CA134882-01A1 2
Showing 10 of 16 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Post GB, Birnbaum LS, DeWitt JC, Goeden H, Heiger-Bernays WJ, Schlezinger JJ. Letter to the editors regarding "The conundrum of the PFOA human half-life, an international collaboration". Regul Toxicol Pharmacol. 2022 Oct; 134:105240. PMID: 35973622; DOI: 10.1016/j.yrtph.2022.105240;
     
  2. Lu D, Demissie S, Horowitz NB, Gower AC, Lenburg ME, Alekseyev YO, Hussein AI, Bragdon B, Liu Y, Daukss D, Page JM, Webster MZ, Schlezinger JJ, Morgan EF, Gerstenfeld LC. Temporal and Quantitative Transcriptomic Differences Define Sexual Dimorphism in Murine Postnatal Bone Aging. JBMR Plus. 2022 Feb; 6(2):e10579.View Related Profiles. PMID: 35229061; PMCID: PMC8861981; DOI: 10.1002/jbm4.10579;
     
  3. Nielsen G, Heiger-Bernays WJ, Schlezinger JJ, Webster TF. Predicting the effects of per- and polyfluoroalkyl substance mixtures on peroxisome proliferator-activated receptor alpha activity in vitro. Toxicology. 2022 01 15; 465:153024.View Related Profiles. PMID: 34743024; PMCID: PMC8692422; DOI: 10.1016/j.tox.2021.153024;
     
  4. Sen P, Qadri S, Luukkonen PK, Ragnarsdottir O, McGlinchey A, Jäntti S, Juuti A, Arola J, Schlezinger JJ, Webster TF, Orešic M, Yki-Järvinen H, Hyötyläinen T. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J Hepatol. 2022 02; 76(2):283-293.View Related Profiles. PMID: 34627976
     
  5. Freid R, Hussein AI, Schlezinger JJ. Tributyltin protects against ovariectomy-induced trabecular bone loss in C57BL/6J mice with an attenuated effect in high fat fed mice. Toxicol Appl Pharmacol. 2021 11 15; 431:115736.View Related Profiles. PMID: 34619157; PMCID: PMC8545923; DOI: 10.1016/j.taap.2021.115736;
     
  6. Kassotis CD, Hoffman K, Völker J, Pu Y, Veiga-Lopez A, Kim SM, Schlezinger JJ, Bovolin P, Cottone E, Saraceni A, Scandiffio R, Atlas E, Leingartner K, Krager S, Tischkau SA, Ermler S, Legler J, Chappell VA, Fenton SE, Mesmar F, Bondesson M, Fernández MF, Stapleton HM. Reproducibility of adipogenic responses to metabolism disrupting chemicals in the 3T3-L1 pre-adipocyte model system: An interlaboratory study. Toxicology. 2021 09; 461:152900. PMID: 34411659; PMCID: PMC8453119; DOI: 10.1016/j.tox.2021.152900;
     
  7. Kim S, Reed E, Monti S, Schlezinger JJ. A Data-Driven Transcriptional Taxonomy of Adipogenic Chemicals to Identify White and Brite Adipogens. Environ Health Perspect. 2021 07; 129(7):77006.View Related Profiles. PMID: 34323617; PMCID: PMC8320370; DOI: 10.1289/EHP6886;
     
  8. Schlezinger JJ, Hyötyläinen T, Sinioja T, Boston C, Puckett H, Oliver J, Heiger-Bernays W, Webster TF. Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPARa mice fed an American diet. Toxicol Appl Pharmacol. 2021 09 01; 426:115644.View Related Profiles. PMID: 34252412; PMCID: PMC8338894; DOI: 10.1016/j.taap.2021.115644;
     
  9. Schlezinger JJ, Heiger-Bernays W, Webster TF. Predicting the Activation of the Androgen Receptor by Mixtures of Ligands Using Generalized Concentration Addition. Toxicol Sci. 2020 10 01; 177(2):466-475.View Related Profiles. PMID: 32726424; PMCID: PMC7548291; DOI: 10.1093/toxsci/kfaa108;
     
  10. de la Rosa R, Schlezinger JJ, Smith MT, Webster TF. Application of generalized concentration addition to predict mixture effects of glucocorticoid receptor ligands. Toxicol In Vitro. 2020 Dec; 69:104975.View Related Profiles. PMID: 32858110; PMCID: PMC7594746; DOI: 10.1016/j.tiv.2020.104975;
     
Showing 10 of 67 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 67 publications over 25 distinct years, with a maximum of 7 publications in 2021

YearPublications
19951
19961
19982
19991
20005
20014
20021
20034
20041
20052
20064
20071
20081
20104
20111
20122
20144
20153
20163
20172
20183
20194
20205
20217
20221

Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Schlezinger's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department